The Serum Institute of India (SII) Saturday said that phase 2 and 3 clinical trials of the Oxford-AstraZeneca COVID-19 vaccine candidate will resume after receiving a green signal from the Drugs Controller General of India (DCGI). Earlier in the day, AstraZeneca said it had resumed the clinical trials of the vaccine following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so, the firm said on Saturday.
The late-stage trials of the vaccine were suspended this week following an adverse reaction in a volunteer in UK. Following this, Serum Institute of India (SII) too had paused the ongoing clinical trials of the vaccine candidate in India.
Cautioning people against lowering their guard till an effective anti-coronavirus medicine is developed, Prime Minister Narendra Modi on Saturday came up with a slogan in Hindi to drive home his point. He said, ‘Jab tak dawai nahi, tab tak dhilai nahi’ (No carelessness till a medicine is found).
India reported nearly 1 lakh (97,570) coronavirus cases in the last 24 hours ending 8 am on Saturday. With this, the total tally went past the 46 lakh-mark to reach 46,59,985. Also, as many as 1,201 deaths reported during the same period pushed the death toll to 77,472. At present, the country has 9,58,316 active cases and 36,24,197 people who have been treated and discharged.
Globally, over 28 million have been affected while 915,356 have succumbed to the virus so far and as many as 19,215,800 have recovered. The United States continued to remain the worst-affected, followed by India and Brazil.